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Objectives. Osteoporosis, in addition to its consequent fracture burden, is a common and costly condition. FRAX® is a well-
established, validated, web-based tool which calculates the 10-year probability of fragility fractures. A FRAX model for Ukraine
has been available since 2016 but its output has not yet been translated into intervention thresholds for the treatment of os-
teoporosis in Ukraine; we aimed to address this unmet need in this analysis. Methods. In a referral population sample of 3790
Ukrainian women, 10-year probabilities of major osteoporotic fracture (MOF) and hip fracture separately were calculated using
the Ukrainian FRAXmodel, with and without femoral neck bone mineral density (BMD). We used a similar approach to that first
proposed by the UK National Osteoporosis Guideline Group, whereby treatment is indicated if the probability equals or exceeds
that of a woman of the same age with a prior fracture. Results.+eMOF intervention threshold in females (the age-specific 10-year
fracture probability) increased with age from 5.5% at the age of 40 years to 11% at the age of 75 years where it plateaued and then
decreased slightly at age 90 (10%). Lower and upper thresholds were also defined to determine the need for BMD, if not already
measured; the approach targets BMDmeasurements to those at or near the intervention threshold. +e proportion of the referral
populations eligible for treatment, based on prior fracture or similar or greater probability, ranged from 44% to 69% depending on
age.+e prevalence of the previous fracture rose with age, as did the proportion eligible for treatment. In contrast, the requirement
for BMD testing decreased with age. Conclusions. +e present study describes the development and application of FRAX-based
assessment guidelines in Ukraine.+e thresholds can be used in the presence or absence of access to BMD and optimize the use of
BMD where access is restricted.
1. Introduction
+e burden of osteoporosis and its related fractures is in-
creasingly recognised; for example, the number of years lived
with a disability is greater for osteoporosis than for any
single cancer, except for lung cancer, and is comparable to or
greater than that due to many chronic noncommunicable
diseases [1, 2]. An estimated 2.7 million hip fractures oc-
curred in 2010 worldwide [3], with around 620,000 hip and
1.8 million other fragility fractures in the EU in the same
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year [4, 5]. +e total cost in the EU, including values of
quality-adjusted life years (QALYs) lost, was estimated at
€98 billion, a figure that is expected to rise to €121 billion in
2025. Among recent developments in the management of
osteoporosis, the use of tools designed to calculate fracture
risk is increasingly adopted to improve the identification of
those at the highest risk who would benefit from appropriate
treatment. Of these, the widely used FRAX® tool (http://
www.sheffield.ac.uk/FRAX) computes the 10-year proba-
bility of a major osteoporotic fracture (MOF, comprising a
hip, spine, forearm, or humerus fractures) or hip fracture
alone from simple, easily captured clinical risk factors
(CRFs) with the optional incorporation of femoral neck
bone mineral density (BMD) measured by dual-energy
Y-ray absorptiometry (DXA) [6, 7]. It is increasingly in-
corporated within national and international guidelines for
osteoporosis [8] with some countries providing direct
linkages between the FRAX assessment and clinical guidance
websites, for example, in the UK [9, 10]. A FRAX calculator,
calibrated to the epidemiology of hip fracture and mortality
in Ukraine, was launched in 2016 but has not yet been linked
to intervention thresholds [11].
A number of approaches have been taken in the de-
velopment of intervention thresholds and are discussed
elsewhere [8]. In brief, within most guidelines, it is rec-
ommended that treatment can be considered in postmen-
opausal women with a history of fracture, regardless of
BMD, with some guidelines restricting this to previous
vertebral or hip fracture. If such patients are eligible for
treatment, then those at similar or greater risk, but without a
previous fracture, should also be considered for treatment.
+is approach, first promoted by the National Osteoporosis
Guideline Group in the UK and subsequently adopted in
European guidance, produces an age-dependent threshold
as the 10-year probability of fracture is in itself age-de-
pendent [10, 12–14]. Given the well-described differences in
fracture epidemiology across countries, the thresholds
should be calibrated to the fracture risk within each country.
In this analysis, we wished to develop these thresholds for
Ukraine and explore their use and impact within a Ukrai-
nian referral population.
2. Methods
2.1. Development of Intervention and Assessment 3resholds.
+e 10-year probabilities of MOF and hip fracture were
calculated using the Ukrainian model of FRAX (version 4.1).
Given the assumption that a prior fracture was considered to
carry a sufficient risk to recommend treatment, the inter-
vention threshold for womenwithout a prior fracture was set
at the age-specific 10-year probability of a MOF equivalent
to women with a previous fragility fracture, but without any
other clinical risk factors. At all ages, the body mass index
(BMI) was set to 25 kg/m2.
In addition to the intervention threshold, two assess-
ment thresholds were derived to enable the clinician to
consider the need for BMD assessment, if the latter had not
already been performed [10]. +ese assessment thresholds,
again based on MOF probabilities, comprised the following.
A lower threshold of probability: this was defined as the
probability of fracture in a woman with BMI of 25 kg/m2 but
without any clinical risk factors, that is, in the absence of
such risk factors, there is no need to consider a BMD test or
treatment.
An upper threshold of probability: defined as a proba-
bility above which treatment could be recommended
without necessarily measuring BMD. To minimise the
likelihood that a woman at high risk of fracture, based on
clinical risk factors alone, would be reclassified to the group
with low risk following a BMD test, the threshold was set at
1.2 times the intervention threshold.
Application of this guideline then results in 4 groups of
patients at first assessment (i.e., before any input from BMD
measurements). +e first group comprises women with a
previous fragility fracture to be considered as eligible for
treatment without any need for further assessment (BMD
could be used to monitor treatment response). +e second
group consists of those women who, following the FRAX
assessment, have low probabilities that lie below the lower
assessment threshold so that no further action is required.
+e third group comprises women without a history of
fracture but with high fracture probability above the upper
assessment threshold in whom treatment should also be
considered. +e final group are those women who, in the
absence of the previous fracture, have a FRAX MOF
probability falling between the lower and upper assessment
thresholds in whom a BMD measurement is mandated with
the fracture probability then recalculated with the inclusion
of this additional information. On recalculation, individuals
are classified as eligible for treatment when the probability
lies above the intervention threshold.
2.2. Impact of3resholds. +e application of these thresholds
was then tested in a referral population of 3790 women
attending the D.F. Chebotarev Institute of Gerontology in
Ukraine for the assessment of osteoporosis between May
2017 and May 2019. +e study was approved by the Ethics
Committee of the D.F. Chebotarev Institute of Gerontology
NAMS of Ukraine (17/05/2017, protocol no. 5) and all
participants provided written informed consent. Bone
density was measured on Hologic or GE Lunar equipment,
with the T-scores converted to Hologic T-score units using
established conversion equations.
2.3. Statistical Analysis. +e analysis was performed by
Statistica 10.0 software. +e sample’s relevance in terms of
the normal distribution principle was checked by Shapir-
o–Wilk’s test. +e data were presented as n (%) and also as
mean values (M) and standard deviation (SD) or median
(Nf) and the lower and upper quartiles (25Q–75Q)
according to data distribution.
3. Results
+e intervention and assessment thresholds, derived from
FRAX MOF probabilities using the Ukraine calculator, are
shown in Table 1 and Figure 1. +e intervention threshold
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increased with age from 5.5% at the age of 40 years to 11% at
the age of 75 years, with a subsequent plateau at age 85 years
and a small decrease thereafter. +e upper and lower as-
sessment thresholds also varied with age and provided
guidance on the need for the measurement of BMD in the
assessment of fracture probability. For example, at the age of
60 years and in the absence of a prior fracture, a BMD test
would be recommended in an individual with a fracture
probability that lay between 4% and 10%. Following recal-
culation of the FRAX MOF probability with the inclusion of
the femoral neck BMD T-score, treatment would be rec-
ommended if the MOF probability was 8.3% or greater.
3.1. Impact of 3resholds. +e baseline characteristics of the
referral population, comprising 3790 women (85% post-
menopausal), are shown in Table 2. +e mean age was 62
years and the mean BMI was 27.8 kg/m2. Prior fracture was
by far the most common clinical risk factor (51.5%), whereas
smoking was very uncommon.
FRAX probabilities could be calculated in 3719 women
(98.1%) due to a small number of women not having clear
information about the causes of secondary osteoporosis. +e
mean probability of a MOF was 6.0%, and for a hip fracture,
it was 1.3% when BMD was not included in the FRAX
calculation. FRAX probabilities for both outputs were higher
when an incident of fracture was included in the calculation
(Table 3). All probabilities showed a skewed distribution as
illustrated for the output of MOF FRAX probability cal-
culated with BMD (Figure 2).
Within the referral cohort, mean FRAX MOF proba-
bilities largely increased progressively with age (Figure 3).
For example, the mean probability calculated without BMD
was 4.4% at age of 40–49 years and was twofold higher at the
age of 80–89 years. Mean FRAX MOF probabilities calcu-
lated with BMD were higher than those calculated without
BMD in most age groups; this was particularly noted at
younger ages, decreased at older ages, and was reversed in
those aged 80–89 years.
When applying the thresholds as described in the
methods to derive the categories of risk, the 1906 women
with prior fracture (51.3% of the 3719 women assessed)
were classified as needing treatment on this basis. Of the
women without prior fracture (n � 1813), only a small
number (27 women, 0.7% of the whole cohort assessed)
had sufficiently high FRAX MOF probabilities to exceed
the upper assessment threshold (Figure 4). In contrast, a
significant proportion (1105 women, 29.7% of the cohort)
were found to have FRAX MOF probabilities that lay
below the lower assessment threshold, suggesting that no
further assessment (including BMD) would be required.
+us, the intermediate category of risk comprised 681
women (18.3% of the whole cohort assessed) in whom
BMD would be assessed and FRAX recalculated with the
inclusion of femoral neck BMD (Figure 4). Of these, 480
women (12.9% of the whole cohort assessed) had final
FRAX MOF probabilities that fell below the intervention
threshold (treatment not recommended), whereas 201
women (5.4% of the cohort) had values at or above the
Table 1: Values of 10-year FRAXMOF probability (%), calculated without BMD using the Ukrainian model of FRAX, for the lower, upper,
and intervention thresholds by age.
Age (years) Lower assessment threshold Upper assessment threshold Intervention threshold#
40 2.4 6.6 5.5
45 2.7 7.3 6.1
50 3.1 8.1 6.7
55 3.5 9.1 7.5
60 4.0 10 8.3
65 4.4 11 8.8
70 5.0 12 9.6
75 6.0 13 11
80 6.7 13 11
85 6.9 13 11
90 6.0 12 10










































Figure 1: Intervention (IT), lower (LAT), and upper (UAT) as-
sessment thresholds based on major osteoporotic fracture proba-
bilities for use with the FRAX tool for Ukraine. Note. Values within
the red area merit consideration of treatment without the need for
BMD, while those in the green area suggest that no further as-
sessment (e.g., BMD) is necessary. Values in the orange area,
around the IT, indicate that femoral neck BMD assessment and
incorporation of the result into the FRAX calculation is warranted.
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intervention threshold and should be recommended
treatment. At the end of the process, a total of 2134 women
(57.4%) would be recommended treatment (Figure 4).
+e final disposition of the cohort in terms of treatment
being recommended and the need for BMD testing is shown
in Figure 5. +e proportion requiring treatment increased
from 44% in women of ages 40–49 years to 69% in those of
ages 70–79 years.Within each age group, a prior fracture was
by far the major factor determining the need for treatment.
+e use of the guidance and thresholds resulted in a low
overall need for BMD testing (19% of the whole cohort as
reported above), but this was also age-dependent with a
greater proportion of the younger age groups needing BMD
compared to a much lower proportion of the older age
groups (Figure 5).
4. Discussion
In this report, we present potential guidelines and thresholds
for the use of 10-year fracture probability by FRAX in
clinical practice in Ukraine. +e thresholds are driven by a
combination of the epidemiology of fracture in Ukraine,
reflected within the FRAX calculator for Ukraine, and a
method for determining intervention thresholds proposed
within European guidance [11, 14]. +e approach provides
for a more restricted but targeted use of DXA-measured
BMDwhich is particularly useful if access to BMD is limited;
the thresholds can indeed be used in the complete absence of
BMD so that patients in regions with limited resources are
Table 2: Characteristics of the referral population.
Variable (description) Mean± SD (range) or n (%)
Age (years) 62.0± 10.0 (40–90)
Height (cm) 162.1± 6.5 (130–187)
Weight (kg) 73.1± 14.5 (39–140)
Body mass index (kg/m2) 27.8± 5.3 (13.9–54.1)
Postmenopausal status, n (%) 3209 (84.7%)
Previous fracture, n (%) 1950 (51.5%)
Parental fracture hip, n (%) 165 (4.4%)
Current smoking, n (%) 4 (0.0%)
Glucocorticoids, n (%) 293 (7.7%)
Rheumatoid arthritis, n (%) 211 (5.6%)
Secondary osteoporosis, n (%) 83 (2.4%)
Alcohol (3 or more units per day), n (%) 63 (1.7%)
BMD of femoral neck (T-score at baselinea,b) −1.7± 1.5 (−5.4–4.3)
aFor Hologic: T-score � (BMD–0.858)/0.120 [9]. bFor GE Lunar: T-score � ((−0.023 + 0.939×BMD–0.019)/1.087–0.858)/0.120) [9, 11].
Table 3: Ten-year probability of the fractures in the studied population.
FRAX Ten-year probability All group Women without fractures Women with fractures
MOF calculated without BMD (%) 6.0 [3.6–8.7] 3.7 [3.1–4.7] 8.4 [6.9–10.0]
Hip fracture calculated without BMD (%) 1.3 [0.5–2.4] 0.6 [0.3–1.1] 2.1 [1.3–3.4]
MOF calculated with BMD (%) 5.9 [3.8–9.2] 3.9 [3.1–5.3] 8.6 [6.3–12.0]
Hip fracture calculated with BMD (%) 1.1 [0.4–2.6] 0.6 [0.2–1.3] 2.1 [1.0–3.9]
Data are presented in Me [Q25-Q75].
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Figure 2: +e distribution of FRAX MOF probabilities in the
referral cohort of 3719 women. In this example, FRAX MOF
probability is calculated with the inclusion of femoral neck BMD.




























Figure 3: Mean FRAX MOF probabilities, calculated with and
without femoral neck BMD, across the age categories within the
referral population.
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not disenfranchised. +e simple rationale is that if post-
menopausal women, of any age, with a previous fragility
fracture, can be recommended treatment to reduce future
fracture risk, as is commonly considered, then an individual
without fracture but with equivalent fracture probability
should also be eligible for treatment.
+e combination of risk assessment and treatment
consideration leads to an easily applicable clinical pathway.
+e starting point is the recognition of the presence of one or
more risk factors in an individual which then triggers the
physician to consider osteoporosis and, more importantly,
fracture risk. +is case-finding strategy has long been pro-
moted in the majority of osteoporosis guidelines, but in the
past led to the advice that BMD measurements should
subsequently be obtained in all patients, with treatment
indicated on the finding of BMD-defined osteoporosis
(lumbar spine or hip BMD T-score< -2.5) [15]. +e role of
detecting BMD-defined osteoporosis was twofold. Firstly,
the evidence base for osteoporosis treatments had largely
been built on randomized clinical trials with BMD-defined
osteoporosis as an entry criterion; this led to the belief by
many that treatments would not work in the absence of
BMD-defined osteoporosis. +is is now rightly regarded as
an incorrect interpretation of the data with several recent
studies confirming that osteoporosis treatments can reduce
fracture risk in patients with BMD above the osteoporosis
threshold [16]. For example, in a 6-year study where women
with osteopenia were randomized to receive 18-monthly
infusions of zoledronate or placebo, osteoporotic fracture
risk was reduced by 37% [17]. In addition, a population-
based UK study of screening for high hip fracture risk using
FRAX showed an overall 28% reduction in hip fractures,
despite half of the treated group having hip BMD above the
osteoporosis range [18]. +e second reason for the detection
of BMD-defined osteoporosis was the frequent requirement
in many countries of a BMD-defined “diagnosis” of oste-
oporosis for reimbursement of any treatment costs. +e
move of clinicians away from the dependence on BMD to the
management of patients based on fracture risk is an issue
that requires further discussion between osteoporosis spe-
cialists, healthcare providers, and payers in the coming
months and years.
In the new clinical pathway, the presence of the clinical
risk factor now mandates a fracture risk assessment by
FRAX, with the measurement of BMD viewed as an addi-
tional risk factor to be assessed in all patients or in a subset.
For countries with less than optimal DXA provision, such as
the UK and many other European countries, the optimal use
of DXA is to limit its use to patients in whom the result
might impact on the decision to treat or not, that is, those
with FRAX probabilities lying at or near an intervention
threshold. In the current study, the proportion of the referral
population requiring scans was substantially reduced from
48.3%, representing all of those without fracture, to only 19%
when confined to those with FRAX probabilities lying be-
tween the upper and lower assessment thresholds. At a
population level in the UK, it has been shown that this more
targeted use of BMD identifies only a slightly reduced
proportion of women at high risk (average 34.6% vs. 35.7%
across all ages), but with lower numbers of scans required at
each age [19]. For example, it required only 3.5 scans at the
age of 50 years to identify one case of hip fracture, whereas
the BMD measurement in all required 13.9 scans per
identified hip fracture.+e acquisition costs for identifying a
hip fracture case and the total costs (acquisition and
treatment) per hip fracture averted were lower [19].
Our analysis has one main limitation.+e FRAX outputs
are calibrated to the best available data on fracture and
mortality within the country of interest; assessment of its
performance is then best performed when the sample reflects
the overall population, whereas the current study is based on
a referral population that is highly unlikely to be repre-
sentative. +is is reflected in the very high prevalence of
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Figure 4: Application of the Ukrainian FRAX MOF assessment
and intervention thresholds to the referral population. +e num-
bers in each category of risk denote the number of women in each
category.













Figure 5: Proportion of women recommended treatment and the
proportion needing BMD tests, by age, when the guidance and
Ukrainian FRAX thresholds are applied to the referral population,
%.
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the major driver of the decision to treat (51.3%), with the
FRAX assessment only adding a modest number of addi-
tional women needing treatment (6.1% of whole cohort or
11.9% of those treated). It is likely that the latter would be of
higher relative importance if, for example, a true population
screening program was undertaken. In the SCOOP study of
population screening in the UK, where only 22% of women
had a history of prior fracture, the proportion identified for
treatment in the absence of fracture was 7.8% of the whole
cohort or 26% of those recommended for treatment [18].
+is rises still further when, as in the SCOOP study, the prior
fracture is handled as a risk factor rather than an inde-
pendent criterion for treatment; in the final high-risk cat-
egory of the SCOOP study, 54.5% of the women were
categorized as such in the absence of a prior fracture [18].
+ese considerations suggest that the low prevalence of
women eligible for treatment is a function of the atypical
referral population rather than in the epidemiology of
fracture in Ukraine. On a separate note, while this use of
FRAX-based intervention in the setting of a case-finding
approach has been shown to be cost-effective in a UK setting
[20], cost-effectiveness is likely to differ in Ukraine because
of different fracture risks and costs. Further studies and
analyses in nonreferral populations in Ukraine would be
useful to further characterize the performance of the in-
tervention and assessment thresholds.
5. Conclusion
+e present study describes the establishment of interven-
tion and assessment thresholds for FRAX-based fracture risk
assessment in Ukraine. Implementation of the approach
described here would enable appropriate treatment of
women at high risk of fracture with a potential substantial
reduction in the use of BMD resources for risk assessment
(the latter may still be needed for monitoring of treatment
response depending on local guidance). +e study highlights
potential disparities between intervention thresholds and
reimbursement criteria and this will need resolution, pos-
sibly by underpinning these guidelines with an economic
assessment. Overcoming these hurdles is, however, very
likely to improve the delivery of health care to those most in
need with high fracture risk.
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